SCHEMBL6582222

SCHEMBL6582222

Cc1ccccc1Nc1nccc(-c2cccnc2-c2ccc(F)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNB2 O95067 8/20 0.56
CDK1 P06493 8/20 0.56
CCNB1 P14635 8/20 0.56
CCNB3 Q8WWL7 8/20 0.56
RET P07949 6/20 0.56
GSK3B P49841 3/20 0.53
DYRK1A Q13627 1/20 0.53
AURKA O14965 1/20 0.44
AURKB Q96GD4 1/20 0.44
TPX2 Q9ULW0 1/20 0.44
PIK3CA P42336 2/20 0.42
PIK3CG P48736 2/20 0.42
CDK4 P11802 1/20 0.42
CDK2 P24941 1/20 0.42
KDR P35968 1/20 0.42
ABL1 P00519 1/20 0.41
BCR P11274 1/20 0.41
PIK3CB P42338 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7481773 0.79 MAPK14 (0.58) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL6795873 0.78 MAPK14 (0.49) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL5256587 0.73 CCNB2 (0.56) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL5258455 0.73 CCNB2 (0.59) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL6581932 0.72 MAPK14 (0.51) RETAURKACDK2KDR
SCHEMBL7475168 0.72 CCNB2 (0.55) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL3769898 0.72 CCNB2 (1.00) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL4373707 0.72 ABL1 (0.72) CCNB2CDK1CCNB1CCNB3RET
SCHEMBL6579207 0.72 MAPK14 (0.53) CDK2
SCHEMBL21317784 0.71 TGFBR1 (0.41) RETGSK3BDYRK1AAURKACDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140083-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-02 EP claimed
US-6469018-B1 INHIBITING CYTOKINES AND THE TREATMENT OF A CYTOKINE MEDIATED DISEASE, BY ADMINISTRATION OF COMPOUNDS SUCH AS:2-(4-FLUOROPHENYL)-3-(2-METHYLTHIOPYRIMIDIN-4-YL)PYRIDINE SMITHKLINE BEECHAM CORPORATION 2002-10-22 US claimed
EP-1140083-A1 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2001-10-10 EP claimed
WO-2000040243-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-13 WO claimed
EP-1140083-A4 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORP (US) 2004-01-02 EP disclosed
US-6469018-B1 INHIBITING CYTOKINES AND THE TREATMENT OF A CYTOKINE MEDIATED DISEASE, BY ADMINISTRATION OF COMPOUNDS SUCH AS:2-(4-FLUOROPHENYL)-3-(2-METHYLTHIOPYRIMIDIN-4-YL)PYRIDINE SMITHKLINE BEECHAM CORPORATION 2002-10-22 US disclosed
EP-1140083-A1 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2001-10-10 EP disclosed
WO-2000040243-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-13 WO disclosed